SAB Biotherapeutics to Present at ADA 84th Scientific Sessions

MIAMI, June 18, 2024 – SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, announced its participation in the ADA 84th Scientific Sessions, held on June 21-24, 2024, in Orlando, Florida. The company will present a poster detailing the tolerance and safety of SAB-142, a human anti-thymocyte immunoglobulin aimed at delaying the progression of type 1 diabetes (T1D). The presentation by Dr. Eric Sandhurst, SAB’s Senior Program Manager, will take place on Sunday, June 23, from 12:30 PM to 1:30 PM, and the poster will also be published online in the journal Diabetes®.

The ADA's Scientific Sessions is recognized as the world's premier conference focused on diabetes research, prevention, and care. Over 11,000 experts, including physicians, scientists, and healthcare professionals, are expected to attend both in person and virtually. Participants will have access to groundbreaking research presentations and opportunities to engage with leading diabetes specialists.

SAB-142 is a novel human alternative to rabbit anti-thymocyte globulin (ATG). Similar to rabbit ATG, which has shown clinical effectiveness in multiple trials for type 1 diabetes, SAB-142 aims to modulate the immune response, slowing the destruction of pancreatic beta cells. Rabbit ATG has demonstrated the capacity to preserve beta cells and maintain insulin production, which is essential for regulating blood sugar levels.

SAB-142 works by targeting multiple immune cells that attack pancreatic beta cells. Unlike rabbit ATG, which can cause serum sickness and anti-drug antibodies due to its animal origin, SAB-142, being a human antibody, is designed to be safer for repeated dosing. This characteristic is crucial for managing type 1 diabetes, a chronic condition requiring long-term treatment.

SAB Biotherapeutics obtained FDA IND clearance for SAB-142 in May and is progressing with its clinical program. This development represents a significant step toward offering a safer and more effective treatment for type 1 diabetes patients.

SAB Biotherapeutics is dedicated to developing human, multi-targeted, high-potency immunoglobulins (IgGs) for treating and preventing immune and autoimmune disorders. The company's lead candidate, SAB-142, targets type 1 diabetes by potentially altering the disease's course. SAB employs advanced genetic engineering to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with human artificial chromosomes, allowing the production of diverse, high-potency human IgGs without human donors or convalescent plasma. This innovative approach addresses many critical unmet medical needs.

SAB Biotherapeutics continues to push the boundaries of immunotherapy with its sophisticated DiversitAb™ drug development platform, which harnesses the power of immune responses to create targeted treatments for various severe conditions. Through its pioneering work, SAB aims to set a new standard in managing and potentially curing chronic diseases like type 1 diabetes.